{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:26:32Z","timestamp":1773804392317,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/s1473-3099(23)00514-5","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T02:03:55Z","timestamp":1700877835000},"page":"224-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control"],"prefix":"10.1016","volume":"24","author":[{"given":"Wenping","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1473-3099(23)00514-5_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.medj.2021.11.006","article-title":"Protection against tuberculosis by Bacillus Calmette-Gu\u00e9rin (BCG) vaccination: a historical perspective","volume":"3","author":"Setiabudiawan","year":"2022","journal-title":"Med"},{"key":"10.1016\/S1473-3099(23)00514-5_bib2","article-title":"Research advances for virus-vectored tuberculosis vaccines and latest findings on tuberculosis vaccine development","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/S1473-3099(23)00514-5_bib3","article-title":"Next-generation TB vaccines: progress, challenges, and prospects","volume":"11","author":"Zhuang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/S1473-3099(23)00514-5_bib4","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","author":"Wajja","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S1473-3099(23)00514-5_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG\u2014implications for a novel tuberculosis vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/S1473-3099(23)00514-5_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime\u2014MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/S1473-3099(23)00514-5_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/S1473-3099(23)00514-5_bib8","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/S1473-3099(23)00514-5_bib9","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2021.01.034","article-title":"Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model","volume":"39","author":"Pinpathomrat","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/S1473-3099(23)00514-5_bib10","first-page":"1133","article-title":"BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size","volume":"4","author":"Floyd","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/S1473-3099(23)00514-5_bib11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/joim.13084","article-title":"BCG scarring and improved child survival: a combined analysis of studies of BCG scarring","volume":"288","author":"Benn","year":"2020","journal-title":"J Intern Med"}],"container-title":["The Lancet Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309923005145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309923005145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T21:21:02Z","timestamp":1741036862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309923005145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1473309923005145"],"URL":"https:\/\/doi.org\/10.1016\/s1473-3099(23)00514-5","relation":{},"ISSN":["1473-3099"],"issn-type":[{"value":"1473-3099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control","name":"articletitle","label":"Article Title"},{"value":"The Lancet Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1473-3099(23)00514-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1473-3099(23)00501-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}